MRKR | tickerfilter.com

Fundamental analysis

22%

Profitability 0%

Dept financing 7%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-8.18%

1 Month

-33.99%

3 Months

-64.69%

6 Months

-61.60%

1 Year

-78.56%

2 Year

24.49%

Key data

Stock price

$1.01

P/E Ratio

0.00

DAY RANGE

$0.95 - $1.05

EPS

-$1.10

52 WEEK RANGE

$0.95 - $5.99

52 WEEK CHANGE

-$78.51

MARKET CAP

25.162 M

YIELD

N/A

SHARES OUTSTANDING

8.923 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

1.76

PUBLIC FLOAT

AVERAGE 10 VOLUME

$66,116

AVERAGE 30 VOLUME

$99,616

Company detail

CEO: Peter L. Hoang
Region: US
Website: markertherapeutics.com
Employees: 60
IPO year: 2007

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Marker Therapeutics, Inc. engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors. It is also developing TPIV100/110 and TPIV200, which is in Phase 2 clinical trials for breast and ovarian cancers.

MRKR - Marker Therapeutics, Inc.